Consumer Duty in insurance: which product can prove its value after the sale?

An insurance product can meet its sales target, pass its annual review and still fail the question that matters: what outcomes did different customers actually receive? The FCA’s insurance work has repeatedly exposed weak links between product design, distributor remuneration, claims experience, support and board decisions. Its thematic review of 28 manufacturers and 39 distributors found that many firms could not adequately assess and evidence fair value, while a separate outcomes-monitoring review saw sparse reporting and limited differentiation between customer groups. That creates a commercial opening for a focused intervention, not another enterprise-wide framework: choose one product and distribution chain, reconstruct the value evidence and decide what must change. This reading explains how insurers, MGAs, brokers and specialist advisers can package that first purchase, convert it into recurring outcome monitoring and acquire clients through real product or supervisory triggers—without promising regulatory approval, claim outcomes or effortless retention.

Consumer Duty requires firms to act to deliver good outcomes for retail customers through the products and services, price and value, consumer understanding and consumer support outcomes, supported by cross-cutting obligations. In insurance, the relevant responsibilities depend on whether the firm manufactures, distributes, services or materially influences the customer outcome.

The perimeter must be mapped product by product. An insurer, MGA, broker and outsourced service provider may each control different decisions and data. A group-level policy does not prove that a specific chain identifies foreseeable harm and acts when outcomes deteriorate.

Fair value asks whether the total price a customer pays is reasonable relative to the benefits and service they can expect. It is not a regulator-set price or profit cap. Cover, exclusions, claims experience, support quality, fees, remuneration and differential outcomes can all matter, so a market-average premium cannot by itself prove value.

The assessment should name the product, target market, data period, customer cohorts, costs, benefits, limitations and decision threshold. In insurance, the difference between the underlying risk price and total price deserves explanation where distribution or administration adds substantial cost without proportionate customer benefit.

Distribution remuneration creates an evidence gap when the manufacturer or broker cannot show what cumulative cost pays for, how it affects the total price and whether the associated service benefits customers. A high commission is not automatically unfair, and a low one does not cure poor cover; the chain must evidence value in the round.

The commercial ledger should map every payment, service and decision right across insurer, MGA, broker, administrator and introducer. Unexplained duplication, weak information sharing or remuneration unrelated to customer benefit becomes a product-remediation question rather than a disclosure footnote.

A paid outcome review should select one product and distribution chain, reconstruct the target market and value assessment, test representative customer cohorts and issue a prioritised decision on pricing, cover, remuneration, communication or support. It should produce accountable actions—not a generic Consumer Duty gap analysis spanning every firm and product.

The first purchase can sample twelve months of claims, complaints, cancellation, support and commission information. It documents data limitations and tests outliers rather than hiding them in portfolio averages. The board should be able to see what evidence supports continued distribution and which finding requires change or further investigation.

Useful metrics connect the product promise to customer experience: claim frequency, acceptance, payout, complaints, cancellation, support wait, failed journeys, renewal outcomes and the distribution of results across relevant customer groups. Profitability and loss ratios can inform the picture, but no single metric demonstrates fair value or good outcomes.

The FCA’s general-insurance value measures create common signals, while firm-level monitoring should go deeper where product design or customer characteristics demand it. Every measure needs a numerator, denominator, period, owner and action threshold so a changing definition cannot manufacture improvement.

The analysis should test whether customers with different needs, tenure, channels or characteristics of vulnerability receive materially different outcomes. Portfolio averages can conceal groups facing lower claims acceptance, higher friction or weaker value. Where the difference is credible, the firm must understand its cause and take proportionate action rather than explain it away.

Segmentation should be purposeful and privacy-aware. The review starts with hypotheses tied to product design and journey friction, not indiscriminate profiling. Missing data becomes a governance issue with an owner and collection plan.

When a firm cannot demonstrate fair value, it should investigate promptly and take action proportionate to the harm. Options may include changing price, benefits, exclusions, remuneration, target market, distribution, communications or support; restricting new sales; and considering customer remediation where harm occurred. Documentation without an operational response is not an outcome.

The decision log records evidence, accountable executive, affected customers, interim protection, deadline and validation method. Complex legal or actuarial judgements remain with qualified specialists. An acquisition adviser can organise demand and the operating system, but cannot certify the regulated conclusion.

The strongest prospects have a product review, distribution-chain change, board challenge, low-value signal, acquisition, new MGA capacity or weak outcome data. Brokers with unexplained remuneration and manufacturers unable to obtain distributor information face different problems, so the campaign should name the role, product and trigger rather than advertise generic compliance support.

Search captures fair-value and Consumer Duty questions; insurance networks, compliance partners and events establish credibility; carefully researched telephone, email and voicemail outreach can test product ownership and timing. Every route should end in a short screen covering scope, authority, accessible data and willingness to act.

The recurring service should refresh fair-value evidence, monitor outcomes by relevant cohort, govern distributor information, track remediation and prepare decisions for product committees and boards. It is valuable when it changes product or customer action. A monthly dashboard with no thresholds, root-cause analysis or accountable response is reporting theatre, not outcome monitoring.

The rhythm can combine monthly signal review, quarterly product decisions and event-driven escalation. Scope states which firm supplies data, who validates actuarial or legal analysis, who communicates with distributors and how customer harm is addressed. That makes the renewal dependent on maintained control, not consultancy inertia.

The offer is ready when the partner can define one insurance audience, review a bounded product chain, access meaningful outcome data, refer regulated judgements and operate remediation monitoring within capacity. GetFishNet’s free eligibility test checks the commercial trigger, proof, first purchase and recurring economics before recommending a campaign.

The opportunity is strongest where the buyer already feels the cost of uncertainty: a product committee cannot defend value, distributor data is missing or a poor outcome needs action. Acquisition should never manufacture alarm or imply that a consultant’s template satisfies the FCA. It should make the next decision easier to buy and safer to operate.

Authorities cited: Financial Conduct Authority; FCA Handbook. Dated references remain in the private source register.